NEW 2-HETEROARYL-SUBSTITUTE BENZIMIDAZOLE DERIVATIVE Russian patent published in 2008 - IPC C07D401/04 C07D401/12 C07D401/14 C07D403/04 C07D405/14 C07D413/04 C07D413/14 C07D417/04 C07D417/14 A61K31/4192 A61K31/4196 A61K31/4245 A61K31/426 A61K31/427 A61K31/433 A61K31/4439 A61K31/444 A61K31/4709 A61K31/497 A61K31/506 A61P3/04 A61P3/10 

FIELD: chemistry.

SUBSTANCE: invention relates to new bonds in the formula (I-0): or its pharmaceutically acceptable salts, where X represents a carbon atom or nitrogen atom; X₁, X₂, X₃ and X₄, each independently, represents a carbon atom or a nitrogen atom; ring A of the formula (II): represents tiazolil, imidazolil, izotiazolil, tiadiazolil, triazolil, oxazolil, oxadiazolil, izoxazolil, pirazinil, piridil, piridazinil, pirazolil or pirimidinil; R¹ represents aryl or represents a 4-10- membered monocyclic or bicyclic heteroring, which has in the ring from 1 to 4 heteroatoms, selected from the group, consisting of a nitrogen atom, sulphur atom and an oxygen atom, and R¹ can be independently substituted with 1-3 R⁴, and, when the specified heteroring is an aliphatic heteroring, then it can have 1 or 2 double bonds; R² independently represents hydroxy, formyl, -CH_3-aF_a, -OCH_3-aF_a, amino, CN, halogen, C_1-6 alkyl or -(CH₂)_1-4OH; R³ represents -C_1-6 alkyl, -(CH₂)_1-6-OH, -C(O)-OC_1-6 alkyl, -C(O)-OC_1-6 alkyl, -(CH₂)_1-6-NH₂, cyano, -C(O)-C_1-6 alkyl, halogen, -C_2-6 alkenyl, -OC_1-6 alkyl, -COOH, -OH or oxo; R⁴ independently represents -C_1-6 alkyl, and the alkyl can be substituted with identical or different 1-3 hydroxyls, halogens, -OC(O)-C_1-6 alkyls, and the alkyl can be substituted with 1-3 halogens or -OC_1-6 alkyls, -C_3-7 cycloalkyl, -C_2-6 alkenyl, -C(O)-N(R⁵¹)R⁵², -S(O)₂-N(R⁵¹)R⁵²,-O-C_1-6 alkyl, and C_1-6 alkylcan be substituted with a halogen or N(R⁵¹)R⁵², -S(O)_0-2-C_1-6 alkyl, -C(O)-C_1-6 alkyl, and C_1-6 alkyl can be substituted with a halogen, amino, CN, hydroxy, -O-C_1-6 alkyl, -CH_3-aF_a, -OC(O)-C_1-6 alkyl, -N(C_1-6 alkyl)C(O)O-C_1-6 alkyl, -NH-C(O)O-C_1-6 alkyl, phenyl, -N(R⁵¹)R⁵², -NH-C(O)-C_1-6 alkyl, -N(C_1-6 alkyl)-C(O)-C_1-6 alkyl or -NH-S(O)_0-2-C_1-6 alkyl, -C(S)-C_3-7 cycloalkyl, -C(S)- C_1-6 alkyl, -C(O)-O- C_1-6 alkyl, -(CH₂)_0-4-N(R⁵³)-C(O)-R⁵⁴, -N(R⁵³)-C(O)-O-R⁵⁴,-C(O)-aryl, it is optional to substitute the halogen, -C(O)-aromatic heteroring, -C(O)-aliphatic heteroring, heteroring, and the heteroring can be substituted with C_1-6 alkyl, optionally substituting the halogen or -O-C_1-6 alkyl, phenyl, optionally substituting the halogen, -C_1-6 alkyl, -O-C_1-6 alkyl, halogen, CN, formyl, COOH, amino, oxo, hydroxy, hydroxyamidine or nitro; R⁵¹ and R⁵², each independently, represents a hydrogen atom, C_1-6 alkyl or a nitrogen atom, R⁵¹ and R⁵² together form 4-7-member heteroring; R⁵³ represents a hydrogen atom or C_1-6 alkyl, R⁵⁴ represents -C_1-6 alkyl or alkyls for R⁵³ and R⁵⁴ and -N-C(O)- together form 4-7-member hydrogen containing heteroring, or alkyls for R⁵³ and R⁵⁴ and -N-C(O)-O- together form 4-7-member hydrogen containing aliphatic heteroring and an aliphatic heteroring can be substituted with oxo, or an aliphatic heteroring can have 1 or 2 double bonds in the ring; X₅ represents -O-, -S-, -S(O)-, -S(O)₂-, a single bond or -O-C_1-6 alkyl; a independently denotes a whole number 1, 2 or 3; q denotes a whole number from 0 till 2; m denotes a whole number from 0 till 2, except in the case when one of the X₅ represents -O-, -S-, -S(O)- or -S(O)₂-, and the other from X₅ represents a single bond, and R¹ represents aryl, optionally substituted with 1-3 R⁴, or a hydrogen containing aromatic heteroring, consisting of from 1 to 4 heteroatoms, selected from the group, comprising of a hydrogen atom, sulphur atom and an oxygen atom, in the case, when X₅, both represent single bonds or in cases, when R¹, both represent aliphatic heteroring. The invention also relates to the bonding in the formula (I-12), and also to the bonding in the formula (I-0), to the pharmaceutical composition, to the glucokinase activator and to the medication.

EFFECT: getting new bioactive compounds which can be used for treatment and/or prophylaxis of diabetes or obesity.

23 cl, 603 ex